Evidence map›Paper›PMID 36691080›Full record

ArticleCritical care (London, England)2023

COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation.

Michael John Patton, Carlos J Orihuela, Kevin S Harrod, Mohammad A N Bhuiyan, Paari Dominic, Christopher G Kevil, Daniel Fort, Vincent X Liu, Maha Farhat, Jonathan L Koff and 6 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Critical care (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Efficacy of Three Kayviruses AgainstAntibiotics (Basel, Switzerland) · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Michael John PattonMedical Scientist Training Program, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. mjpatton@uab.edu.
Carlos J OrihuelaDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Kevin S HarrodDepartment of Anesthesiology and Perioperative Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Mohammad A N BhuiyanDepartment of Internal Medicine, Division of Clinical Informatics, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, USA.
Paari DominicDepartment of Medicine, Division of Cardiovascular Sciences, University of Iowa, Iowa City, IA, USA.
Christopher G KevilDepartments of Pathology, Molecular and Cellular Physiology, and Cellular Biology and Anatomy, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, USA.
Daniel FortOchsner Health System, New Orleans, LA, USA.
Vincent X LiuKaiser Permanente Division of Research, Oakland, CA, USA.
Maha FarhatHarvard University Medical School, Boston, MA, USA.
Jonathan L KoffDepartment of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Yale University, New Haven, USA.
Charitharth V LalDepartment of Pediatrics, Neonatology Division, University of Alabama at Birmingham, Birmingham, AL, USA.
Anuj GaggarArriveBio, San Francisco, CA, USA.
Robert P RichterDepartment of Pediatrics, Division of Pediatric Critical Care, University of Alabama at Birmingham, Birmingham, AL, USA.
Nathaniel Erdmann *Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.
Matthew Might *Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham, Birmingham, AL, USA.
Amit Gaggar *Department of Medicine, Pulmonary, Allergy, and Critical Care Medicine Division, University of Alabama at Birmingham, Birmingham, AL, USA.
University of Alabama at Birmingham · USLouisiana State University Health Sciences Center Shreveport · USHarvard University · USKaiser Permanente · USOchsner Health System · USUniversity of Iowa · USYale University · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
Cardiac microlesion formation during invasive pneumococcal diseaseR01AI114800 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Carlos J Orihuela, Herve S TETTELIN · 2015 to 2026
$5.1M
A Novel Proteolytic System of Pulmonary InflammationR01HL102371 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GAGGAR, AMIT · 2010 to 2021
$3.3M
PspA binds necroptotic cells to cause disease and transmitR01AI156898 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ORIHUELA, CARLOS J · 2020 to 2024
$2.0M
Influenza regulation of epithelial pneumococcal host defense.R01HL149944 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HARROD, KEVIN S · 2020 to 2023
$1.5M
Mechanisms driving endothelial angiopoietin-2 expression and vascular dysfunction during pediatric sepsisK08GM144788 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RICHTER, ROBERT P · 2021 to 2025
$930k
Viral adaptation to CD4 T cell responses and the impact on HIV immunityK08AI129705 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ERDMANN, NATHANIEL BERNARD · 2017 to 2021
$930k
Neutrophil Exosomes: New Pathogenic Entities in COPDI01CX001969 · VA · BIRMINGHAM VA MEDICAL CENTER · PI GAGGAR, AMIT · 2020 to 2025
–
CSRD VA I01 CX001969NHLBI NIH HHS R01 HL102371NHLBI NIH HHS R01 HL149944NIAID NIH HHS K08 AI129705NIAID NIH HHS R01 AI114800NIAID NIH HHS R01 AI156898NIGMS NIH HHS K08 GM144788NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

backgroundRecent single-center reports have suggested that community-acquired bacteremic co-infection in the context of Coronavirus disease 2019 (COVID-19) may be an important driver of mortality; however, these reports have not been validated with a multicenter, demographically diverse, cohort study with data spanning the pandemic.

methodsIn this multicenter, retrospective cohort study, inpatient encounters were assessed for COVID-19 with community-acquired bacteremic co-infection using 48-h post-admission blood cultures and grouped by: (1) confirmed co-infection [recovery of bacterial pathogen], (2) suspected co-infection [negative culture with ≥ 2 antimicrobials administered], and (3) no evidence of co-infection [no culture]. The primary outcomes were in-hospital mortality, ICU admission, and mechanical ventilation. COVID-19 bacterial co-infection risk factors and impact on primary outcomes were determined using multivariate logistic regressions and expressed as adjusted odds ratios with 95% confidence intervals (Cohort, OR 95% CI, Wald test p value).

resultsThe studied cohorts included 13,781 COVID-19 inpatient encounters from 2020 to 2022 in the University of Alabama at Birmingham (UAB, n = 4075) and Ochsner Louisiana State University Health-Shreveport (OLHS, n = 9706) cohorts with confirmed (2.5%), suspected (46%), or no community-acquired bacterial co-infection (51.5%) and a comparison cohort consisting of 99,170 inpatient encounters from 2010 to 2019 (UAB pre-COVID-19 pandemic cohort). Significantly increased likelihood of COVID-19 bacterial co-infection was observed in patients with elevated ≥ 15 neutrophil-to-lymphocyte ratio (UAB: 1.95 [1.21-3.07]; OLHS: 3.65 [2.66-5.05], p < 0.001 for both) within 48-h of hospital admission. Bacterial co-infection was found to confer the greatest increased risk for in-hospital mortality (UAB: 3.07 [2.42-5.46]; OLHS: 4.05 [2.29-6.97], p < 0.001 for both), ICU admission (UAB: 4.47 [2.87-7.09], OLHS: 2.65 [2.00-3.48], p < 0.001 for both), and mechanical ventilation (UAB: 3.84 [2.21-6.12]; OLHS: 2.75 [1.87-3.92], p < 0.001 for both) across both cohorts, as compared to other risk factors for severe disease. Observed mortality in COVID-19 bacterial co-infection (24%) dramatically exceeds the mortality rate associated with community-acquired bacteremia in pre-COVID-19 pandemic inpatients (5.9%) and was consistent across alpha, delta, and omicron SARS-CoV-2 variants.

conclusionsElevated neutrophil-to-lymphocyte ratio is a prognostic indicator of COVID-19 bacterial co-infection within 48-h of admission. Community-acquired bacterial co-infection, as defined by blood culture-positive results, confers greater increased risk of in-hospital mortality, ICU admission, and mechanical ventilation than previously described risk factors (advanced age, select comorbidities, male sex) for COVID-19 mortality, and is independent of SARS-CoV-2 variant.

Indexed as

BacteremiaCoinfectionCommunity-Acquired InfectionsCOVID-19BacteriaCohort StudiesHospital MortalityHumansIntensive Care UnitsMalePandemicsRespiration, ArtificialRetrospective StudiesRisk FactorsSARS-CoV-2

Identifiers

PMID36691080
PMCPMC9868503
OpenAlexW4317717850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.